Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Newitt

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Analytical Biochemistry|June 6, 2009
Assessing compound binding to the Eg5 motor domain using a thermal shift assayPatricia A McDonnell, Joseph Yanchunas, John A Newitt, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding modeStephen T Wrobleski, Shuqun Lin, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2023
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1Jay A Markwalder, Aaron J Balog, David K Williams, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate CancerAudris Huang, Lata Jayaraman, Aberra Fura, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitorsKyoung Soon Kim, Songfeng Lu, Lyndon A Cornelius, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation PathwayJames J Mignone, Elizabeth A Jurica, Deepa Rajasekaran, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Analytical Biochemistry|June 6, 2009
Assessing compound binding to the Eg5 motor domain using a thermal shift assayPatricia A McDonnell, Joseph Yanchunas, John A Newitt, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding modeStephen T Wrobleski, Shuqun Lin, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2023
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1Jay A Markwalder, Aaron J Balog, David K Williams, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate CancerAudris Huang, Lata Jayaraman, Aberra Fura, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitorsKyoung Soon Kim, Songfeng Lu, Lyndon A Cornelius, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|September 25, 2025
Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation PathwayJames J Mignone, Elizabeth A Jurica, Deepa Rajasekaran, et al.
Pageof 5